Homeslice, they loss $0.03 per share last quarter and the merger didn't go through until then end of Q2.
Biosante had $3,087,000 in operating expenses even if they eliminated it entirely it would be somewhat offset by a $1 million sale for GVAX. No Biosante operating cost - $1 million = $2,087,000 which tranlates into $0.22 assuming they managed to pare half of it for the quarter that would be $0.11
Then when looking at the inventory data including work in progress for ANI from 2012 Q4 to 2013 Q1, I am guessing an increase revenues of 15 to 20 % and a similar rise in income from continued operations over 2013 Q1, adding maybe 1 to 2 cents per share to the bottom line.
I would guess $0.10 EPS this quarter. At least $0.20 EPS plus whatever refer next quarter as rest of Biosante costs and interest cost for ANI are washed out.
Who knows we may get a bigger surprise. But $0.50 is a lot to ask for, but who knows.